D M Grasela
Overview
Explore the profile of D M Grasela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grasela T, Dement C, Kolterman O, Fineman M, Grasela D, Honig P, et al.
Clin Pharmacol Ther
. 2007 Jul;
82(2):137-42.
PMID: 17632539
As the transition to model-based drug development continues, pharmacometric analysis will have an increasingly important role across the entire life cycle of drug discovery, development, regulatory approval, and commercialization. For...
2.
Nord C, Meurling L, Russo R, Bello A, Grasela D, Gajjar D
J Chemother
. 2003 Jul;
15(3):244-7.
PMID: 12868550
Garenoxacin is a new des-F(6)-quinolone with a broad antimicrobial spectrum. It has been reported that antibiotics may raise digoxin concentrations in the plasma of patients who are taking these agents...
3.
Gajjar D, Bello A, Ge Z, Christopher L, Grasela D
Antimicrob Agents Chemother
. 2003 Jun;
47(7):2256-63.
PMID: 12821477
Garenoxacin (T-3811ME, BMS-284756) is a novel des-F(6) quinolone that has been shown to be effective in vitro against a wide range of clinically important pathogens, including gram-positive and gram-negative aerobes...
4.
Nord C, Gajjar D, Grasela D
Clin Microbiol Infect
. 2002 Jun;
8(4):229-39.
PMID: 12047415
Objective: BMS-284756 (T-3811ME) is a novel des-F(6)-quinolone effective against a broad spectrum of aerobic and anaerobic pathogens. The aim of this study was to investigate the ecological effect of BMS-284756...
5.
Ambrose P, Grasela D, Grasela T, Passarell J, Mayer H, Pierce P
Antimicrob Agents Chemother
. 2001 Sep;
45(10):2793-7.
PMID: 11557471
Fluoroquinolone antibiotic agents have demonstrated efficacy in the treatment of respiratory tract infections. This analysis was designed to examine the relationship between drug exposure, as measured by the free-drug area...
6.
7.
Ambrose P, Grasela D
Diagn Microbiol Infect Dis
. 2000 Dec;
38(3):151-7.
PMID: 11109013
Background: For fluoroquinolones, AUC:MIC ratios correlate with maximal bacterial eradication in in vitro models of infection and favorable cure rates in humans with respiratory tract infection. Inter-subject pharmacokinetic and MIC...
8.
Grasela D
Clin Infect Dis
. 2000 Sep;
31 Suppl 2:S51-8.
PMID: 10984329
Gatifloxacin is an advanced-generation, 8-methoxy fluoroquinolone that is active against a broad spectrum of pathogens, including antibiotic-resistant Streptococcus pneumoniae. The drug has high oral bioavailability (96%), and, therefore, oral and...
9.
Grasela D, Stoltz R, Barry M, Bone M, Mangold B, OGrady P, et al.
Antimicrob Agents Chemother
. 2000 Jul;
44(8):2149-53.
PMID: 10898689
Two open-label studies assessed the pharmacokinetics of single orally administered doses of 40 mg of stavudine in subjects with renal impairment. In one study (study I), 15 subjects with selected...
10.
Grasela D, Christofalo B, Kollia G, Duncan G, Noveck R, Manning Jr J, et al.
Pharmacotherapy
. 2000 Jun;
20(6 Pt 2):87S-94S.
PMID: 10850525
Study Objectives: To assess the safety and pharmacokinetics of oral gatifloxacin 400 mg in subjects with and without hepatic impairment, and the need to modify doses in patients with hepatic...